Skip to content

Effects of Essential and Non-Essential Amino Acids on Post-Exercise Muscle Collagen Synthesis in Young Men

The Effects of Essential and Non-Essential Amino Acids on Post-Exercise Muscle Collagen Synthesis in Young Men: a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04596553
Acronym
PECS
Enrollment
17
Registered
2020-10-22
Start date
2021-01-25
Completion date
2022-02-13
Last updated
2023-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skeletal Muscle, Extracellular Matrix, Amino Acids Metabolism, Exercise, Dietary Supplements

Keywords

Muscle Collagen Turnover, Myofibrillar Protein Synthesis, Extracellular Matrix, Anabolism Signaling, Resistance Exercise, Skeletal Muscle, Bone Turnover

Brief summary

The purpose of this study is to assess which amino acids are affecting acute muscle collagen synthesis in response to supplementation and exercise.

Detailed description

This is a double-blinded, randomized controlled, parallel design study, with 3 treatment groups (placebo, collagen peptide, and essential amino acid). The study will involve 3 visits: a baseline testing/familiarization session, and 2 exercise trials which will include muscle biopsies, blood draws, and the infusion of a tracer isotope in order to measure muscle protein synthesis.

Interventions

DIETARY_SUPPLEMENTEssential Amino Acid

Immediately following the exercise intervention participants will consume their assigned essential amino acid supplement

DIETARY_SUPPLEMENTCollagen Peptide

Immediately following the exercise intervention participants will consume their assigned collagen peptide supplement

DIETARY_SUPPLEMENTMaltodextrin Placebo

Immediately following the exercise intervention participants will consume their assigned maltodextrin supplement

Sponsors

University of British Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Intervention model description

\- Double-blinded, randomized controlled, parallel design study, with 3 treatment groups (placebo, collagen peptide, and essential amino acid)

Eligibility

Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Can fluently read and write in English * Male * 18 - 35 years

Exclusion criteria

* Diabetes, cardiovascular disease, or current pharmaceutical therapy * Medical conditions impacting ability to undertake strenuous physical activity * Lower body resistance training in the previous 6 months * BMI \> 30 * Currently smoking with cigarettes * Allergy to any study supplements * Currently taking any protein, amino acid, or collagen supplement * Participate in greater than 2 hours of weekly vigorous exercise

Design outcomes

Primary

MeasureTime frameDescription
Fractional synthetic rate (change over time) of Myofibrillar Protein Synthesis0 - 4 hours post-exerciseFraction of the myofibrillar enriched protein from muscle biopsy per unit time.
Fractional synthetic rate (change over time) Muscle Collagen Synthesis0 - 4 hours post-exerciseFraction of the intramuscular collagen enriched protein from muscle biopsy per unit time.
Pro-Collagen Type I N-Propeptide (PINP)1 hour prior to exerciseOsteoblastic marker of bone collagen synthesis

Secondary

MeasureTime frameDescription
Plasma Amino Acids Response to Supplementation0 - 4 hours post-exerciseAmino acid plasma concentrations
Pro-Collagen Type III N-Propeptide (PIIINP)1 hour prior to exerciseMarker of collagen synthesis
Muscle mechanistic target of rapamycin Pathway Activation0 - 4 hours post-exerciseMeasuring the fold change in enzymes associated with the anabolic signalling of the mTOR pathway (e.g. phosphoinositide 3-kinases (PI3k), protein kinase B (Akt))
PCR Gene Expression of Muscle Collagen Genes (Types I, III, IV)0 - 4 hours post-exerciseMeasuring the fold change when the collagen genes of interest become detectable in the PCR analysis

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026